TRACON Pharma shares are trading lower after the company said envafolimab plus Yervoy did not demonstrate synergy in cancer patients compared to single agent envafolimab, and it will terminate enrollment in cohort D.
Portfolio Pulse from Benzinga Newsdesk
TRACON Pharma announced that envafolimab plus Yervoy did not demonstrate synergy in cancer patients compared to single agent envafolimab, leading to the termination of enrollment in cohort D.
June 20, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TRACON Pharma's stock is trading lower after the company reported that envafolimab plus Yervoy did not show synergy in cancer patients, leading to the termination of enrollment in cohort D.
TRACON Pharma's stock price is likely to be negatively impacted in the short term due to the disappointing results of the envafolimab plus Yervoy combination in cancer patients. The termination of enrollment in cohort D indicates a setback in the company's clinical trials, which could affect investor sentiment and lead to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100